

Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (S.161.3)


| Product Details | |
|--------------------|--|
| Size | 100 µL |
| Species Reactivity | Human, Mouse |
| Published Species | Human |
| Host/Isotype | Rabbit / IgG |
| Class | Monoclonal |
| Type | Antibody |
| Clone | S.161.3 |
| Conjugate | Unconjugated |
| Immunogen | Synthetic peptide corresponding to residues surrounding Tyr694 of Stat5a |
| Form | Liquid |
| Concentration | 380 µg/mL |
| Purification | Affinity chromatography |
| Storage buffer | 0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/mL BSA, 50% glycerol |
| Contains | <0.02% sodium azide |
| Storage conditions | -20°C |
| RRID | AB_10980279 |

| Applications | Tested Dilution | Publications |
|---|-----------------|----------------|
| Western Blot (WB) | 1:500 | 3 Publications |
| Immunohistochemistry (Paraffin) (IHC (P)) | 1:600 | - |
| Flow Cytometry (Flow) | 1:100 | - |
| Immunoprecipitation (IP) | 1:50 | - |

Product Specific Information


It is not recommended to aliquot this antibody.

Product Images For Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (S.161.3)




Phospho-STAT5 alpha (Tyr694) Antibody (MA5-14973)

Altered expression of target protein upon cell treatment demonstrates antibody specificity. Western blot analysis of Phospho-STAT5 alpha (Tyr694) using Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (Product # MA5-14973) shows basal expression in K-562 and HEL 92.1.7 cell lines. Expression was reduced upon treatment with tyrosine kinase inhibitors Imatinib and Dasatinib in K-562. Whereas, treatment with JAK-inhibitor Tofacitinib reduced expression in HEL 92.17 but not K-562, which is resistant to the drug. {TM}



Phospho-STAT5 alpha (Tyr694) Antibody (MA5-14973) in WB

Western blot analysis was performed on whole cell extracts (30 µg lysate) of K-562 (Lane 1), K-562 treated with Imatinib (1 µM for 2 h) (Lane 2), Imatinib (5 µM for 2 h) (Lane 3), Dasatinib (1 mM for 4 h) (Lane 4), and Tofacitinib (1 µM/M for 48 h) (Lane 5), HEL 92.1.7 (Lane 6) and HEL 92.1.7 treated with Tofacitinib (1 µM /M for 48 h) (Lane 7). The blot was probed with Anti-Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (Product # MA5-14973, 1:500 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (Heavy Chain) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg /mL, 1:4,000 dilution). A 90 kDa band corresponding to Phospho-STAT5 alpha (Tyr694) was observed in K-562 and HEL 92.1.7 at basal levels. Expression was reduced upon treatment with tyrosine kinase inhibitors Imatinib and Dasatinib in K-562. Whereas, treatment with JAK-inhibitor Tofacitinib reduced expression in HEL 92.17 but not K-562, which is resistant to the drug.



Phospho-STAT5 alpha (Tyr694) Antibody (MA5-14973) in IHC (P)

Immunohistochemical analysis of Phospho-STAT5 pTyr694 in paraffin-embedded human breast carcinoma using a Phospho-STAT5 pTyr694 monoclonal antibody (Product # MA5-14973).

View more figures on thermofisher.com

Western Blot (3)

| | |
|---|---|
| <p>Archives of toxicology</p> <p>Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.</p> <p>"MA5-14973 was used in Western Blotting to test whether a combined inhibition of mutant FMS-like tyrosine kinase and class I histone deacetylases are effective against Acute myeloid leukemia cells."</p> <p>Authors: Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulkko M, Piée-Staffa A, Brachetti C, Haehnel PS, Sellmer A, Mahboobi S, Kindler T, Brenner W, Nikolova T, Krämer OH</p> | <p>Year 2022</p> <p>Species Human</p> |
| <p>Cancers</p> <p>Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition.</p> <p>"MA5-14973 was used in Western Blot to uncover which pathways control the transition of the hydroxyurea-induced replication stress into an apoptotic programme in myeloid leukaemia cells."</p> <p>Authors: Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F, Krämer OH</p> | <p>Year 2021</p> <p>Species Human</p> |

[View more WB references on thermofisher.com](#)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (i) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (ii) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (iii) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (iv) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.